<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002401</url>
  </required_header>
  <id_info>
    <org_study_id>228F</org_study_id>
    <secondary_id>0074</secondary_id>
    <nct_id>NCT00002401</nct_id>
  </id_info>
  <brief_title>A Study of Delavirdine Used Together With Other Anti-HIV Drugs in HIV-Infected Patients</brief_title>
  <official_title>An Open-Label Randomized Study of Delavirdine Mesylate (DLV, Rescriptor) in Triple and Quadruple Combinations With Zidovudine (ZDV), Indinavir (IDV), and Lamivudine (3TC) in HIV-1 Infected Individuals</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pharmacia and Upjohn</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to see if it is safe and effective to give delavirdine (DLV) in&#xD;
      combination with two or three other drugs to HIV-infected patients. The drugs to be used in&#xD;
      combination with DLV are zidovudine (ZDV), indinavir (IDV), and lamivudine (3TC).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this open-label pilot study, patients are randomized to 1of the following 4 arms for 24&#xD;
      weeks:&#xD;
&#xD;
      Arm 1 (40 patients): DLV plus ZDV plus IDV. Arm 2 (40 patients): DLV plus IDV plus 3TC*. Arm&#xD;
      3 (40 patients): DLV plus ZDV plus IDV plus 3TC. Arm 4 (40 patients): ZDV plus IDV plus 3TC.&#xD;
&#xD;
        -  Dose determined by body weight. Patients may opt to continue on study for 24 additional&#xD;
           weeks at the discretion of the investigator.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>160</enrollment>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Indinavir sulfate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Delavirdine mesylate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lamivudine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zidovudine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
        Less than 1 month prior treatment with zidovudine.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Prior indinavir.&#xD;
&#xD;
          -  Prior lamivudine.&#xD;
&#xD;
          -  Prior protease inhibitors.&#xD;
&#xD;
          -  Prior non-nucleoside reverse transcriptase inhibitors.&#xD;
&#xD;
          -  1 month or more prior zidovudine.&#xD;
&#xD;
             1. HIV-1 positive.&#xD;
&#xD;
          -  CD4 coun tis above 50.&#xD;
&#xD;
          -  HIV-1 RNA levels greater than 20,000.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Pharmacia &amp; Upjohn</name>
      <address>
        <city>Peapack</city>
        <state>New Jersey</state>
        <zip>07977</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 1999</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>HIV-1</keyword>
  <keyword>Zidovudine</keyword>
  <keyword>HIV Protease Inhibitors</keyword>
  <keyword>Lamivudine</keyword>
  <keyword>Indinavir</keyword>
  <keyword>RNA, Viral</keyword>
  <keyword>Delavirdine</keyword>
  <keyword>Reverse Transcriptase Inhibitors</keyword>
  <keyword>Viral Load</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Zidovudine</mesh_term>
    <mesh_term>Delavirdine</mesh_term>
    <mesh_term>Indinavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

